Effect of Spironolactone on Atrial Fibrillation in Patients with Heart Failure with Preserved Ejection Fraction: Post-Hoc Analysis of the Randomized, Placebo-Controlled TOPCAT Trial

• Published in: American journal of cardiovascular drugs : drugs, devices, and other interventions devices, and other interventions, 2020-02, Vol.20 (1), p.73-80
• Main Authors: Neefs, Jolien, van den Berg, Nicoline W. E., Krul, Sébastien P. J., Boekholdt, S. Matthijs, de Groot, Joris R.
• Format: Article
• Language: English
• Subjects: Blood pressure; Cardiac arrhythmia; Cardiology; Confidence intervals; Health risk assessment; Heart failure; Hospitalization; Medicine; Medicine & Public Health; Original; Original Research Article; Patients; Peptides; Pharmacology/Toxicology; Pharmacotherapy
• ISSN: 1175-3277; 1179-187X
• DOI: 10.1007/s40256-019-00353-5

Background Mineralocorticoid receptor antagonists (MRAs) reduce the risk of atrial fibrillation (AF) in patients with heart failure (HF) and a reduced ejection fraction. The efficacy of MRAs for AF prevention in patients with HF and a preserved ejection fraction (HFpEF) is unclear. Objectives We performed a secondary analysis of a randomized placebo-controlled trial to determine the efficacy of spironolactone in reducing new-onset AF and recurrence of AF in 2733 patients with symptomatic HFpEF. Methods Patients with and without prevalent AF at baseline were included, and those with permanent AF were excluded. Patients were randomized 1:1 to spironolactone or placebo. The risk of new-onset AF or the recurrence of AF was quantified using hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). Results At baseline, 2228 (64.7%) patients had no history of AF (spironolactone, n = 1111; placebo, n = 1117), whereas 505 (18.4%) patients had prevalent AF (spironolactone, n = 260; placebo, n = 245). During a median follow-up of 3.1 years (interquartile range [IQR] 2.0–4.9), the incidence of new-onset AF was similar in both treatment arms: spironolactone 5.2% ( n = 58) versus placebo 4.4% ( n = 49); p = 0.41. The risk of new-onset AF was similar in both treatment arms: HR 1.19; 95% CI 0.81–1.74; p = 0.38. AF recurrence was also similar in both treatment arms during a median follow-up of 3.3 years (IQR 1.9–4.7): spironolactone 11.5% ( n = 30) versus placebo 11.8% ( n = 29); p = 1.00. The risk of recurrence of AF did not differ per treatment arm: HR 0.94; 95% CI 0.57–1.58; p = 0.83. Conclusion Spironolactone does not reduce the risk of new-onset AF or AF recurrence in patients with HFpEF. This is in contrast to results in cohorts of patients with HF and a reduced ejection fraction. Clinical trial registration ClinicalTrials.gov identifier no. NCT00094302 (TOPCAT).